U.S. Chemicals Stock News

Commercial Bancgroup (CBK) opened Q1 2026 with trailing twelve month revenue of US$89.9 million and basic EPS of US$2.95, framed by a net profit margin of 41.4% over the last year compared with 36.3% in the prior year. Over the past reported periods, revenue has moved from US$86.6 million in Q4 2024 to US$89.9 million on a trailing basis, while quarterly basic EPS ranged from US$0.46 in Q4 2024 to US$0.77 in Q3 2025. This sequence gives investors a clear line of sight on recent top and bottom...

Watsco (WSO) has put fresh numbers on the table for Q1 2026, with recent quarters showing revenue of about US$1.6 billion in Q4 2025, basic EPS of US$1.77 and net income of US$67.1 million as a reference point for where the business is coming from. Over the past few quarters, revenue has moved between US$1.5 billion and US$2.1 billion while basic EPS ranged from about US$1.77 to US$4.53, giving you a clear view of how the top line and EPS have tracked together. Set against forecasts for...

Allegion Q1 2026 earnings snapshot Allegion (ALLE) has kicked off Q1 2026 with investors focused on how its recent run of quarterly revenue just above US$1.0b and EPS in the US$1.70 to US$2.20 range feeds into the latest set of numbers. The company has seen revenue move from US$945.6m in Q4 2024 to US$1,033.2m in Q4 2025, while quarterly EPS shifted from US$1.66 to US$1.71 over the same period. This sets a clear baseline for how the new quarter will be judged. With a trailing net profit...

S&P Global (SPGI) has just wrapped up 2025 with fourth quarter revenue of US$3.9b and basic EPS of US$3.76, setting the stage for its Q1 2026 update against a backdrop of rising trailing twelve month revenue and earnings. Over the last six reported quarters, revenue has moved from US$3.6b in Q3 2024 to US$3.9b in Q4 2025 while quarterly basic EPS has ranged from US$2.85 to US$3.86. This has contributed to trailing twelve month EPS of US$14.67 and revenue of US$15.3b by the end of 2025. With a...

Applied Industrial Technologies (AIT) heads into its Q3 2026 update with a recent track record that has revenue moving from US$1,073.0 million in Q2 2025 to US$1,163.0 million in Q2 2026, while basic EPS has shifted from US$2.43 to US$2.54 over the same period, alongside trailing 12 month earnings growth of 4.6%. Over the last year, total revenue on a trailing basis has gone from US$4.48 billion to US$4.75 billion, with trailing EPS ticking from US$10.02 to US$10.65 as net profit margin holds...

Wondering if Carrier Global at around US$61.91 is offering fair value or if you are paying too much for its future potential? This article walks through the numbers in plain language so you can judge for yourself. Over shorter timeframes, the stock shows returns of 0.4% over 7 days, 14.1% over 30 days, 15.7% year to date and 3.8% over the past year, while the 3 year and 5 year returns sit at 56.8% and 52.2% respectively. Recent coverage of Carrier Global has focused on its role in building...

If you are wondering whether Atlanticus Holdings at around US$79.39 still offers value, you are in the right place to assess what that price might actually represent. The stock has had a strong run, with recent total returns of 8.8% over 7 days, 50.6% over 30 days, 19.7% year to date, 42.7% over 1 year, 177.7% over 3 years and 151.3% over 5 years. These moves have come alongside ongoing attention on Atlanticus Holdings within the Consumer Finance space, as investors weigh how its business...

AppFolio, Inc. recently reported first-quarter 2026 results showing sales of US$262.21 million and net income of US$42.42 million, alongside higher earnings per share year over year. The company also raised its full-year 2026 revenue outlook to between US$1.11 billion and US$1.13 billion, underlining management’s confidence in ongoing demand and platform adoption. With full-year revenue guidance now lifted, we’ll examine how this stronger outlook reshapes AppFolio’s investment narrative,...

Freeport-McMoRan (NYSE:FCX) is being linked to a new tech-focused narrative tied to copper demand from the upcoming SpaceX IPO. Major financial media are highlighting copper's role in satellite connectivity and telecommunications infrastructure build outs. This frames Freeport-McMoRan as a potential supplier to the next phase of global connectivity, not only as a traditional copper miner. For readers tracking NYSE:FCX, this fresh angle comes on top of an already strong share price history,...

Carvana is adding Inspection and Reconditioning Center capabilities to its ADESA Syracuse auction site. The expansion is expected to increase vehicle reconditioning capacity and support faster delivery times for customers in New York. The project includes new hiring at the Syracuse facility, bringing additional jobs to the local area. For investors tracking NYSE:CVNA, this build out of physical operations offers context alongside the current share price of $406.73. The company has 3 year...

Genuine Parts (NYSE:GPC) has rolled out Manhattan Active Warehouse Management at its Brisbane distribution centre. The new system replaces legacy platforms and manual workflows across the facility. The move forms part of a wider supply chain modernization effort following recent board changes and activist involvement. For a company built around auto and industrial parts distribution, the way Genuine Parts moves inventory is central to its business model. This shift to a modern warehouse...

Everforth, Inc. ( NYSE:EFOR ) shareholders (or potential shareholders) will be happy to see that the CEO & Director...

Omnicom Group (NYSE:OMC) has announced new AI powered partnerships with Google Cloud and Adobe focused on influencer marketing and enterprise marketing workflows. The Google Cloud collaboration targets automated compliance and editing for influencer campaigns through generative AI tools. The Adobe partnership centers on building an industry specialized AI agentic platform and unified operating model for enterprise marketers. For investors watching NYSE:OMC, these moves come as the stock...

Kilroy Realty Corporation recently reported first-quarter 2026 results, with revenue of US$270.05 million roughly flat year on year but shifting from net income of US$39.01 million to a net loss of US$19.27 million, or US$0.16 loss per share from continuing operations. Despite this move into a loss, the company’s funds from operations of US$0.91 per share exceeded analyst expectations, highlighting the difference between accounting earnings and cash generation that many investors focus on...

If you are wondering whether Ameren at around US$111.91 is still reasonably priced or starting to look stretched, the answer depends on how you look at value. The stock has returned 0.6% over the past week, 2.9% over the past month, 11.0% year to date, 16.4% over 1 year, 37.0% over 3 years, and 52.1% over 5 years. These performance figures naturally get investors thinking about both growth potential and changing risk. Recent attention on regulated utilities, including Ameren, has centered on...

Sirius XM Holdings (NasdaqGS:SIRI) is reported to be in early merger talks with iHeartMedia. The discussions focus on combining satellite radio, streaming audio, and terrestrial broadcast under one company. The talks are described as preliminary, with no confirmed transaction terms or timeline. Sirius XM Holdings operates subscription based satellite radio and audio streaming services, while iHeartMedia runs a large portfolio of terrestrial radio stations and digital audio platforms. A...

The United States market remained flat over the last week but has experienced a significant 30% increase over the past year, with earnings forecasted to grow by 16% annually. In such an environment, identifying stocks that are trading below their intrinsic value can present opportunities for investors seeking potential gains while aligning with projected growth trends.

In the last week, the market has stayed flat, yet it is up 30% over the past year with earnings forecast to grow by 16% annually. In this environment, identifying high growth tech stocks involves looking for companies that demonstrate strong innovation and adaptability within a rapidly evolving sector.

Kestra Medical Technologies (KMTS) has drawn investor attention after recent trading left the shares around $22.23, with a mixed return profile across the past week, month and past 3 months. See our latest analysis for Kestra Medical Technologies. The recent 14.23% 1 month share price return contrasts with weaker year to date share price performance of 8.86% and a 1 year total shareholder return of 11.50%. This suggests short term momentum has picked up while longer term returns remain under...

The United States market remained flat over the last week but has seen a notable 30% increase over the past year, with earnings forecasted to grow by 16% annually. In such an environment, growth companies with high insider ownership can be particularly appealing as they often signal strong internal confidence and alignment with shareholder interests.

In the last week, the U.S. market has stayed flat, but over the past 12 months, it has risen by 30%, with earnings expected to grow by 16% per annum in the coming years. Amidst these conditions, identifying stocks with solid fundamentals and growth potential is crucial for investors looking to capitalize on market opportunities. Penny stocks may be an outdated term, but they still represent a valuable investment area; when backed by strong financials and balance sheet strength, these smaller...

The United States market has experienced a flat performance over the last week but has seen a significant 30% increase over the past year, with earnings projected to grow by 16% annually. In this dynamic environment, identifying stocks that combine strong fundamentals and growth potential can be key to uncovering hidden opportunities in the market.

If you are wondering whether Medpace Holdings at around US$421 per share is still offering value after a strong multi year run, the key is to look past the headline price and into what buyers are actually paying for the business. The stock has recently seen a 20.3% decline over 7 days and a 6.6% decline over 30 days, although the 1 year return sits at 41.3% and the 3 year return at 104.1%. Recent coverage has focused on Medpace as a contract research organization supporting clinical...

Relay Therapeutics scheduled a special call to present new clinical data on its Zovegalisib triplet therapy in breast cancer. The company plans to discuss the combination treatment results and their implications for its development programs. The announcement focuses on Zovegalisib in a triplet regimen, which may be relevant for investors following Relay Therapeutics drug pipeline. Relay Therapeutics, listed as NasdaqGM:RLAY, is drawing attention with a dedicated update on Zovegalisib, a key...